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Resistance to cancer immunotherapy mediated by
apoptosis of tumor-inﬁltrating lymphocytes
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Despite impressive clinical success, cancer immunotherapy based on immune checkpoint
blockade remains ineffective in many patients due to tumoral resistance. Here we use the
autochthonous TiRP melanoma model, which recapitulates the tumoral resistance signature
observed in human melanomas. TiRP tumors resist immunotherapy based on checkpoint
blockade, cancer vaccines or adoptive T-cell therapy. TiRP tumors recruit and activate tumor-
speciﬁc CD8+ T cells, but these cells then undergo apoptosis. This does not occur with
isogenic transplanted tumors, which are rejected after adoptive T-cell therapy. Apoptosis of
tumor-inﬁltrating lymphocytes can be prevented by interrupting the Fas/Fas-ligand axis, and
is triggered by polymorphonuclear-myeloid-derived suppressor cells, which express high
levels of Fas-ligand and are enriched in TiRP tumors. Blocking Fas-ligand increases the anti-
tumor efﬁcacy of adoptive T-cell therapy in TiRP tumors, and increases the efﬁcacy of
checkpoint blockade in transplanted tumors. Therefore, tumor-inﬁltrating lymphocytes
apoptosis is a relevant mechanism of immunotherapy resistance, which could be blocked by
interfering with the Fas/Fas-ligand pathway.
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Inhibitory antibodies against immune checkpoint moleculesCTLA4 and PD1 induce durable tumor responses in a numberof cancer patients, and have become standard of care in a
number of metastatic malignancies. Yet clinical beneﬁt of anti-
CTLA4 and anti-PD1 remains limited to a fraction of patients
and the priority is to understand why the majority of patients fail
to respond. There is mounting evidence indicating that immu-
notherapy resistance is largely dependent on the tumor micro-
environment, whose immunosuppressive nature is progressively
shaped during the long-term process of tumor development in an
immunocompetent host. There are numerous cellular and
molecular mechanisms at play, and the challenge is to deﬁne
those that are clinically relevant. This is traditionally based on
preclinical studies, which often rely on murine transplanted
tumor models. However, transplanted tumors do not recapitulate
the tumor microenvironment as it progressively develops during
the growth of an autochthonous tumor. This is better modeled
using genetically engineered mouse models (GEMM), in which
autochthonous tumors develop following the induction of onco-
genic events within host tissues. However, most available GEMM
models either do not express deﬁned tumor antigens, precluding
in-depth analysis of the anti-tumor immune responses in the
course of immunotherapy, or express model antigens such as
ovalbumin or viral antigens, which are highly immunogenic and
do not reﬂect the poor immunogenicity of tumor antigens that
are naturally expressed on human tumors. To circumvent these
issues, we created the GEMM model of inducible melanomas
expressing P1A, a deﬁned mouse tumor antigen of the
MAGE type55, which we chose as the best representative of the
clinically relevant group of human MAGE-type tumor antigens
encoded by cancer-germline genes1. This model, named TiRP, is
based on the tamoxifen-induced and Cre-lox-mediated induction
of H-RasG12V and deletion of Ink4a/Arf in melanocytes2. The H-
RasG12V transgene is followed by an internal ribosome entry site
(IRES) and the P1A coding sequence (Trap1a), so that all mela-
nomas express P1A and are recognized by P1A-speciﬁc CD8+
T cells directed against the dominant P1A epitope, a nine-amino
acid peptide presented by H-2Ld2. To ensure H-2Ld presentation,
we backcrossed the model from B6 to B10.D2 mice, which are B6
congenic for H-2d. This TiRP model now gives a high incidence
of melanomas (±95%) with a short latency (30–60 days
depending on the tamoxifen batch). Induced TiRP melanomas
are initially well differentiated and highly pigmented (Mela
tumors), but then rapidly undergo dedifferentiation resulting in
white aggressive tumors (Amela), characterized by Epithelial-to-
Mesenchymal Transition (EMT)-like and TGFβ signatures3. This
mesenchymal transition is accompanied by abnormal inﬂam-
mation, involving recruitment of immature myeloid cells, which
appear to impair anti-tumor immunity4. The Amela tumor sig-
nature shares many genes with the innate anti-PD1 resistance
(IPRES) signature that was recently described in human mela-
nomas resisting anti-PD1 therapy, including EMT-like genes
(Axl, Twist2, Loxl2), angiogenesis genes (Vegfa) and monocyte/
macrophage recruitment genes (Ccl2, Ccl7)3, 5. The TiRP model
therefore provides an ideal platform to study immunotherapy
resistance in a manner that is more relevant than transplanted
tumors and recapitulates human tumors resisting
immunotherapy.
In this report, we conﬁrm that TiRP tumors are resistant to
different forms of immunotherapy, and we link this resistance to
the ability of TiRP tumors to induce tumor-inﬁltrating lympho-
cytes (TIL) apoptosis. Anti-tumor T cells recruited to TiRP
tumors quickly undergo apoptosis and disappear. Therefore, they
fail to reject the tumor and to persist. This happens with auto-
chthonous TiRP tumors, but not with isogenic transplanted
tumors. TIL apoptosis is triggered by Fas-ligand, which is
expressed by polymorphonuclear myeloid-derived suppressor
cells (PMN-MDSC). The latter are enriched in induced TiRP
tumors as compared to transplanted isogenic tumors. Adminis-
tration of soluble Fas-Fc can prevent TIL apoptosis and improve
the efﬁcacy of immunotherapy.
Results
Induced TiRP melanomas resist immunotherapy. Immu-
notherapy based on checkpoint inhibitors anti-CTLA4 and anti-
PD1 proved unable to alter the growth of tamoxifen-induced
TiRP tumors, whether given alone or in combination (Fig. 1a).
Because TiRP tumors express MAGE-type tumor antigen P1A,
we also tested a preventive vaccination against P1A using an
established prime/boost immunization scheme based on P1A-
recombinant adenovirus and Semliki Forest virus (SFV), which
induces high levels of P1A-speciﬁc CD8+ T cells and signiﬁcant
protection against a challenge injection of P1A-positive tumor
cells6. However, immunization of TiRP mice before tumor
induction with tamoxifen failed to prevent tumor onset, and this
was not improved upon combination of vaccine with anti-CTLA4
and anti-PD1 (Fig. 1a). This was seemingly not due to loss of
antigen expression, as the tumors that appeared in vaccinated
mice still expressed high amounts of P1A transcripts (Supple-
mentary Fig. 1). These results suggested a strong immunosup-
pressive mechanism preventing T-cell attack of TiRP tumors.
We then used H-2Ld-P1A tetramers to monitor P1A-speciﬁc
CD8+ T cells in the spleen of vaccinated mice stimulated one
week in vitro with the P1A peptide (LPYLGWLVF) (Fig. 1b)49.
All vaccinated mice developed an anti-P1A CD8+ response. In
control mice without tumor, this response persisted until at least
70 days after vaccination. However, in mice developing a TiRP
tumor, the P1A-speciﬁc CD8+ T-cell response plummeted to the
levels of unimmunized mice at day 70. Hence, the presence of a
TiRP tumor induced complete disappearance of the P1A-speciﬁc
anti-tumor CD8+ response. We also observed that non-
vaccinated mice developing a TiRP tumor spontaneously
mounted a P1A-speciﬁc immune response, conﬁrming that TiRP
tumors express the P1A antigen and indicating that the tumor is
immunogenic. However, as observed in vaccinated mice, this
anti-tumor immune response did not persist. This lack of
persistence was restricted to anti-tumor CD8+ T cells, because
when we immunized mice against both P1A and an irrelevant
antigen named P91A (an H-2Ld-restricted mutated peptide7), we
observed that the CD8+ response against the latter antigen
persisted in tumor-bearing mice (Fig. 1c). Moreover, tumor-
bearing mice were able to mount a normal primary CTL response
against minor histocompatibility antigens (Supplementary Fig. 2),
indicating that tumor development did not induce a general CTL
unresponsiveness, as reported previously in a spontaneous sporadic
tumor mouse model8, 9. In the latter model, increased levels of
TGFβ1 were measured in the serum of tumor-bearing mice, and
correlated with the general T-cell unresponsiveness observed after a
long latency period8, 9. Therefore, we also measured TGFβ1 levels in
the serum of tumor-bearing TiRP mice (Supplementary Fig. 3).
Total TGFβ1 levels were high in both groups and increased in
tumor-bearing mice as compared to tumor-free mice. However, the
levels of active TGFβ1 were low and similar in both groups,
indicating that most of the seric TGFβ1 is in its latent, inactive
form. Altogether, our data do not suggest a lack of general T-cell
responsiveness, but rather indicate a selective suppression of tumor-
speciﬁc CTL in tumor-bearing TiRP mice.
Induced but not transplanted tumors resist adoptive cell
therapy. To better track the fate of tumor-speciﬁc CD8+ T cells in
this model, and to evaluate another clinically relevant immu-
notherapy approach, we resorted to adoptive transfer of P1A-
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speciﬁc CD8+ T cells isolated from mice transgenic for the anti-
P1A T-cell receptor (TCR) (TCRP1A mice in the Rag1−/− B10.D2
background)10. Mice bearing induced Amela TiRP tumors
received an intravenous injection of 10 million CD8+
T cells isolated from TCRP1A mice and stimulated 4 days in vitro
(Fig. 2a). Strikingly, this adoptive cell therapy (ACT) was unable
to alter the growth of induced TiRP tumors (Fig. 2b). In parallel,
we used tumor cell line T429, which was previously established
from an induced Amela TiRP tumor and grown in vitro4. We
established isogenic transplanted tumors by subcutaneous injec-
tion of cells from a T429 clone, and we treated these mice with
ACT as above. In contrast to induced tumors, those transplanted
tumors were efﬁciently rejected by adoptively transferred
TCRP1A CD8+ T cells (Fig. 2c). Similar results were obtained
with distinct clones from line T429 and with tumors transplanted
in the subcutaneous (Fig. 2d) or the intradermal space, which is
the natural niche for melanoma development (Fig. 2e). Because of
the identical genetic background of the tumor cells, this striking
difference between induced and transplanted tumors likely
resulted from differences in the tumor microenvironment, and
underlines the relevance of autochthonous tumor models as
opposed to transplanted tumor models for preclinical evaluation
of cancer immunotherapy.
We then analyzed the persistence of TCRP1A CD8+ T cells in
the spleen and lymph nodes of mice 22 days after ACT, using H-
2Ld-P1A tetramers ex vivo. P1A-speciﬁc CTL were easily detected
in tumor-free mice and in mice bearing transplanted tumors.
However, they were undetectable in mice bearing an induced
tumor (Fig. 2f). We then used TCR-speciﬁc clonotypic PCR as a
more sensitive approach, but we also failed to detect TCRP1A
T cells after 22 days in the spleen of mice bearing induced tumors,
while we easily detected them in tumor-free and tumor-
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Fig. 1 Induced TiRP tumors resist immunotherapy. a Schedule for tumor induction and immunotherapy. TiRP mice (B10.D2;Ink4a/Arfﬂox/ﬂox;TiRP+/+)
injected twice with 4mg 4OH-tamoxifen on day 0 and 15, were also injected as indicated with anti-CTLA4 (4 × 40 µg) and/or anti-PD1 (4 × 200 µg) and/
or a prime/boost vaccine regimen of recombinant adenovirus (Adeno.Ii.P1At) and Semliki Forest virus (SFV.P1A) encoding the MAGE-type tumor antigen
P1A. Tumor appearance and mice survival were monitored. The ﬁgure represents the cumulative data of three experiments. b Tumor-bearing TiRP mice
and control mice (B10.D2;Ink4a/Arfﬂox/ﬂox mice, which have the same genetic background as TiRP mice but lack the TiRP transgene) were immunized with
the P1A vaccine as above, and the P1A-speciﬁc CD8+ T-cell response was monitored by FACS in spleen cells stimulated one week with P1A-peptide pulsed
spleen cells, using antibodies to CD3ε and CD8α, and H-2Ld-P1A tetramers. Five mice were analyzed at each time point for each group. c TiRP mice were
immunized simultaneously against P1A as above and against the irrelevant H-2Ld-restricted antigen P91A (mutated peptide) by intramuscular injections of
P91A peptide in AS15 adjuvant52 one week apart during 1 month. Mice were then treated with 4OH-tamoxifen. At the time of tumor appearance, spleen
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using the relevant H-2Ld tetramers. Results are expressed as mean + s.e.m. Unpaired t-test, two-tailed c, *P< 0.05, **P< 0.01
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transplanted mice (Supplementary Fig. 4a). At this time point,
TCRP1A T cells were also absent in most of the induced tumors
themselves (Supplementary Fig. 4a). These results indicated that
tumor-speciﬁc T cells were actively deleted in mice bearing
induced Amela TiRP tumors, while they were not in mice bearing
transplanted tumors.
Induced tumors trigger apoptosis of tumor-speciﬁc T cells. To
understand the fate of tumor-speciﬁc T cells, we then analyzed
mice earlier, 4 days after ACT. At this time, both induced and
transplanted tumors were inﬁltrated by CD8+ T cells (Fig. 3a),
and transferred TCRP1A CD8+ T cells were easily detected in
induced tumors by clonotypic PCR (Supplementary Fig. 4b). Ex
vivo tetramer analysis further showed that transferred T cells
were enriched in the tumors as compared to the spleen and
draining lymph nodes, in both induced and transplanted tumors
(Fig. 3b). These results indicated that transferred TCRP1A CD8+
T cells effectively migrated into the induced tumors in the ﬁrst
days after adoptive transfer. Furthermore, those tumor-
inﬁltrating T cells expressed activation marker CD69, indicating
that they recognized the P1A tumor antigen on tumor cells
(Fig. 3c). To further evaluate the functional capacity of
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Fig. 2 Rejection of transplanted but not induced autochthonous tumors after adoptive transfer of tumor-speciﬁc CD8+ T cells. a Adoptive transfer protocol.
Mice bearing induced autochthonous Amela TiRP tumors or transplanted isogenic tumors received intravenously 107 CD8+ T cells that were isolated from
TCRP1A B10.D2 mice and activated 4 days in vitro by co-incubation with lethally irradiated cells expressing P1A and B7-1 (L1210.P1A.B7-1). b TiRP mice
bearing induced Amela tumors 22–24 days after 4OH-tamoxifen injection received adoptive transfer (n= 32) of 107 TCRP1A CD8+ T cells activated in vitro
for 4 days (red symbols). Black symbols show control mice (n= 30) receiving no T cells. Tumor volume is shown. (Data accumulated from two identical
experiments). c Mice (B10.D2;Ink4a/Arfﬂox/ﬂox) were injected subcutaneously with 2 × 106 cells from clone 11 of isogenic tumor line T429, which had
previously been adapted to culture from an induced Amela TiRP tumor. After 36 days, mice received an intravenous injection of 107 activated TCRP1A
CD8+ T cells (blue symbols). Control mice received no T cells (black symbols). Tumor volume was monitored. Results are shown from one representative
experiment (n= 6/group) out of at least three performed. d Same as in panel c but using another clone (T429.6) from tumor line T429. Mice received 107
activated TCRP1A CD8+ T cells (green symbols) or not (black symbols) 18 days after tumor injection. Results are shown from one representative experiment
(n= 6−7/group) out of at least three performed. e B10.D2;Ink4a/Arfﬂox/ﬂox mice were injected intradermally (2 × 106 cells) with three distinct clones of
tumor line T429. When tumors reached a size of about 400mm3, mice received an intravenous injection of 107 activated TCRP1A CD8+ T cells (colored
curves). Black symbols indicate control mice that received no T cells. Tumor growth was monitored. Individual growth curves are shown (8–10 mice/group).
f Mice treated as in panels b–d were killed 22 days after T-cell transfer, and cells from the spleen and the draining lymph nodes were tested ex vivo (i.e.
without in vitro stimulation) for the presence of P1A-speciﬁc T cells by FACS using H-2Ld-P1A tetramer. The number of mice analyzed is indicated for each
group. Results are expressed as mean± s.e.m
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transferred T cells in the early days after ACT, we tested their
ability to kill P1A-peptide pulsed target cells in an in vivo killing
assay performed 3 days after transfer (Supplementary Fig. 5). We
observed efﬁcient killing of P1A-positive targets in mice bearing
induced tumors, even though it was slightly reduced as compared
with tumor-free mice. Thus, the results so far indicated that
transferred TCRP1A CD8+ T cells retained their functional
capacity, inﬁltrated the induced tumors, recognized their antigen
and became activated. This raised the question: why did they fail
to reject the induced tumors?
We then observed that 4 days after adoptive transfer, a high
proportion of P1A-speciﬁc CD8+ T cells inﬁltrating the induced
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Fig. 3 In vivo apoptosis of tumor-inﬁltrating CD8+ T cells 4 days after transfer. aMice bearing induced (n= 14) or transplanted (n= 13) tumors (500mm3)
received adoptive transfer of TCRP1A CD8+ T cells as in Fig. 2. Four days later, tumors were analyzed by FACS ex vivo for CD8+ T cells among living cells.
b–d Draining lymph nodes (LN), spleens and tumors from tumor-bearing mice were analyzed 4 days after adoptive transfer of TCRP1A CD8+ T cells by
ex vivo FACS staining for CD8 and H-2Ld-P1A tetramers b, CD69 c, and with Annexin V d (for b–d: n= 75 mice for induced tumors, n= 75 mice for
T429.11, n= 32 mice for T429.6, n= 12 for tumor-free mice). e H-2Ld-P1A tetramer-negative CD8+ T cells inﬁltrating induced tumors or spleens from
tumor-free mice were stained for Annexin V. Mice were identical to b–d (induced tumors: n= 75, spleens from tumor-free mice: n= 12). f Mice bearing
induced (n= 4) or transplanted (n= 3) tumors (500mm3) were transferred with activated TCRP1A CD8+ T cells. Four days after transfer, they received an
i.v. injection of FLIVO (inhibitor-based pan-caspase probe) 4 h before killing. Apoptosis of TCRP1A CD8+ T cells was evaluated ex vivo by FACS staining for
FLIVO. Mice receiving a non-targeting FLIVO control dye showed no staining of TCRP1A CD8+ T cells. g Slices (300 µm) of fresh tumor tissues were
incubated with CMAC-stained TCRP1A CD8+ T cells for 24 h. Cryosections (7 μm) were stained for apoptosis using inhibitor-based active pan-caspase
marker FLICA, and scanned with a MIRAX digital microscope. Data were quantiﬁed using Biopix software (n= 5 mice/group; three sections analyzed per
mouse). h TiRP mice bearing either pigmented (Mela) or unpigmented (Amela) induced tumors were treated and analyzed as in b–d (n= 20 mice/group).
Results are expressed as mean + s.e.m. Unpaired t-test, two-tailed a–h, *P< 0.05, **P< 0.01, ***P< 0.001. ****P< 0.0001
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tumors were apoptotic, as deﬁned by staining with Annexin V
(Fig. 3d). This was not the case in transplanted tumors (Fig. 3d).
The non P1A-speciﬁc CD8+ T cells that inﬁltrated induced
tumors were not stained with Annexin V (Fig. 3e). This suggested
that induced tumors resisted immune rejection by triggering
apoptosis of tumor-speciﬁc T cells. Because of the high
background staining observed in spleen and lymph nodes with
Annexin V, we used a series of other approaches to reveal
apoptosis. 4 days after T-cell transfer, we injected mice with
FLIVO, a ﬂuorescent inhibitor-based pan-caspase marker that
selectively binds active caspases and was developed for in vivo
use11. After 4 h, we killed the mice and analyzed TIL by FACS
after staining with H-2Ld-P1A tetramer. We observed that
approximately 50% of P1A-speciﬁc TIL were stained with FLIVO
in induced tumors, while only about 10% were in transplanted
tumors (Fig. 3f). We also analyzed sections of those tumors by
immunoﬂuorescence, monitoring cells positive for FLIVO and for
CellTracker Blue CMAC Dye, which was used to stain T cells
before adoptive transfer. This conﬁrmed the higher proportion of
apoptotic TCRP1A CD8+ T cells in induced tumors (Supple-
mentary Fig. 6a). Similar results were obtained with tumors from
mice adoptively transferred but not treated with FLIVO, which
were stained with antibodies to cleaved caspase-3 and to V-
alpha8, the alpha chain of the TCR used in TCRP1A CD8+ T cells
(Supplementary Fig. 6b, c). Lastly, we tried to recapitulate
apoptosis induction by collecting tumors ex vivo and incubating
freshly cut tumor slices with CMAC-labeled TCRP1A CD8+
T cells for 24 h. We then stained cryosections of these tumor
slices with FLICA, a ﬂuorescent inhibitor-based marker of
activated pan-caspases, and again we observed more apoptotic
TCRP1A CD8+ T cells in induced as compared with transplanted
tumors (Fig. 3g).
We then performed ACT in pigmented (Mela) and unpig-
mented (Amela) induced TiRP tumors, and compared P1A-
speciﬁc CD8+ TIL 4 days after transfer. We observed equal T-cell
inﬁltration and activation, but T-cell apoptosis was restricted to
Amela tumors, suggesting that the ability to induce T-cell
apoptosis was linked to the inﬂammatory microenvironment that
is typical of Amela tumors in this model (Fig. 3h)4.
TIL apoptosis is dependent on Fas-ligand. We then tried to
understand what triggered apoptosis of anti-tumor T cells in
induced tumors. Interferon-gamma (IFNγ) can play a dual role in
the course of the immune response, contributing to an efﬁcient
response by promoting effector T-cell differentiation and MHC
class I expression on the one hand, but also, on the other hand,
inducing inhibitory molecules that contribute to the negative
feedback of the immune response, including IDO, FasL and
PDL112–15. Four days after T-cell transfer, induced tumors con-
tained high levels of IFNγ mRNA and secreted protein, con-
ﬁrming the functionality of transferred T cells (Fig. 4a, b). To
determine whether this IFNγ played a role in the induction of T-
cell apoptosis, we injected an IFNγ-neutralizing antibody into
mice bearing induced tumors 1 day before ACT. Four days after
ACT, we observed a strong reduction in the number of apoptotic
TILs, indicating the involvement of IFNγ in triggering T-cell
apoptosis at the tumor site (Fig. 4c).
A number of genes induced by IFNγ encode proteins that can
trigger lymphocyte apoptosis. These include IDO12, 15, PDL112, 16
and Fas-ligand17. IDO was only weakly expressed in this model,
and only barely increased after T-cell transfer. In contrast, PDL1
was well expressed in this model4. However, it was not involved in
TIL apoptosis because the injection of an anti-PD1 blocking
antibody failed to prevent apoptosis of transferred T cells
(Supplementary Fig. 7a). This was in line with the lack of
therapeutic effect of PD1 blockade in this model (Fig. 1a).
Expression of Fas-ligand (FasL) transcripts was observed in TiRP
tumors, increased after T-cell transfer, and was dramatically
reduced after IFNγ neutralization (Fig. 4d). Moreover, FasL
expression was higher in induced TiRP tumors as compared to
transplanted T429 tumors (Fig. 4e). We therefore investigated the
Fas-FasL pathway as potentially involved in triggering apoptosis of
tumor-inﬁltrating T cells. We ﬁrst used siRNA to silence Fas in
TCRP1A CD8+ T cells and make them insensitive to FasL-
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mediated apoptosis, and we optimized the conditions so that Fas
silencing was effective for at least 7 days (Supplementary Fig. 8).
We then transferred Fas-silenced TCRP1A CD8+ T cells into mice
bearing induced TiRP tumors, and analyzed TIL apoptosis after
4 days, by FACS staining with Annexin V and for activated
caspases (FLICA). We observed a strong reduction of apoptosis of
Fas-silenced TIL (Fig. 5a). We obtained similar results when we
incubated Fas-silenced TCRP1A CD8+ T cells 24 h in vitro with
fresh slices of induced tumors (Fig. 5b). To conﬁrm this result, we
then used soluble Fas-Fc to neutralize FasL in vivo. We injected
mice bearing induced tumors with 150 µg Fas-Fc every day starting
1 day before ACT. Again we observed a clear reduction in the
number of apoptotic TILs after 4 days (Fig. 5c). Fas-Fc also reduced
apoptosis of TCRP1A CD8+ T cells incubated in vitro with fresh
slices of induced tumors (Fig. 5d). We conclude that the apoptosis
of anti-tumor CD8+ T cells observed in induced tumors is mostly
driven by FasL. Tumor necrosis factor alpha (TNFα) is another
factor known to induce T-cell apoptosis18. Even though TNFα is
not clearly induced by IFNγ, we tested its involvement in T-cell
apoptosis in the TiRP model by injecting an anti-TNFα
neutralizing antibody 1 day before and 2 days after ACT. We
observed no reduction of T-cell apoptosis on day 4 after ACT
(Supplementary Fig. 7b). These results supported a dominant role
of FasL in triggering T-cell apoptosis in the TiRP model.
PMN-MDSC trigger TIL apoptosis. We then compared the
cellular composition of the tumor tissue of induced (Amela) and
transplanted tumors. Both tumor types contained CD45+ cells
(hematopoietic origin), which were more abundant in induced
tumors. This likely resulted from a signiﬁcant enrichment of
induced tumors in polymorphonuclear-myeloid-derived sup-
pressor cells (PMN-MDSC) (P< 0.0001, t-test), while monocytic
myeloid-derived suppressor cells (M-MDSC) were equally
represented in both tumor types (Fig. 6a). MDSC are a subset of
immature myeloid cells that can be recruited at tumor sites and
display immunosuppressive activity19. This PMN-MDSC
enrichment was observed in Amela but not in Mela tumors
(Fig. 6b). As compared with M-MDSC, PMN-MDSC produced
more ROS, expressed less iNOS and produced less NO, in line
with previous reports20, 21 (Supplementary Fig. 9). They also
expressed higher levels of arginase, another immunosuppressive
factor that is often expressed in M-MDSC but also in PMN-
MDSC20–23. We conﬁrmed the immunosuppressive function of
these PMN-MDSC by showing their ability to suppress in vitro
proliferation and cytolytic activity of anti-tumor CD8+ T cells at a
1/1 ratio (Fig. 6c, b). Moreover, when we established transplanted
tumors by co-injecting T429.11 tumor cells with PMN-MDSC
(isolated from induced tumors) at a 4 to 1 ratio and then treated
mice with ACT, the co-injected tumors resisted immune rejec-
tion, while control tumors were rejected (Fig. 6e). These results
conﬁrmed the key role of PMN-MDSC in resistance of tumors to
immunotherapy in this model. To explain the higher recruitment
of PMN-MDSC in induced as compared with transplanted
tumors, we measured the expression of a series of cytokines and
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chemokines known to play a role in the recruitment or differ-
entiation of MDSC24, 25. We found that most of them were
expressed at a higher level in induced tumors as compared with
transplanted tumors (Fig. 6f, g). Among these factors, Csf3, Cxcl1
and Cxcl5 are known to speciﬁcally recruit PMN-MDSC24–26.
Although Ccl2, Cxcl12 and TGFβ are mostly known for their
ability to recruit M-MDSC, they can also promote accumulation
of PMN-MDSC in some tumor settings21, 24–26. In addition, it has
been suggested that M-MDSC recruited at the tumor site can be
subsequently converted into PMN-MDSC in the tumor micro-
environment27. These results could therefore explain the accu-
mulation of PMN-MDSC in induced Amela TiRP tumors, and
corroborate our previous observations of increased expression of
such factors, including Ccl2, Cxcl5 and Ccl7, in Amela TiRP
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tumors as compared to Mela TiRP tumors, which recruit much
less MDSC3, 4. Interestingly, overexpression of CCL2 and CCL7
was also reported in human metastatic melanomas that resist
anti-PD1 therapy, and is a cardinal feature of the IPRES
signature5.
Having shown that TIL apoptosis in the TiRP model was
mediated by FasL, we then analyzed FasL expression on cells from
the tumor tissue to determine which cell type was responsible for
inducing TIL apoptosis. We consistently observed high levels of
FasL on MDSC (Fig. 7a, b). Lower levels of FasL were also
observed on endothelial cells and, although inconsistently, on
tumor cells. This expression proﬁle was identical whether we
analyzed tumors collected before or after ACT (Fig. 7a, b). FasL
expression was equally high on PMN-MDSC and M-MDSC
(Fig. 7c), but only the former were enriched in induced as
compared with transplanted tumors (Fig. 6a). This result
suggested that PMN-MDSC were responsible for TIL apoptosis.
This conclusion was supported by in vitro experiments showing
that PMN-MDSC induced apoptosis of co-cultured TCRP1A
CD8+ T cells, the extent of which was reduced by FasL
neutralization with soluble Fas-Fc (Fig. 7d, e). Moreover, TIL
apoptosis was reduced in vivo when we depleted PMN-MDSC by
intra-tumoral injection of anti-Ly6G antibody (Fig. 7f).
To determine whether in vivo FasL neutralization could
increase the efﬁcacy of ACT, we treated mice bearing induced
tumors with soluble Fas-Fc starting one week before ACT, and
followed tumor growth. We observed better tumor control in
mice receiving ACT combined with Fas-Fc, as compared with
mice receiving ACT alone (Fig. 8a, b). Even though Ly6G-
antibody mediated depletion of PMN-MDSC combined with
ACT showed some effect (Fig. 8b), when combined with Fas-Fc
and ACT, PMN-MDSC depletion did not further improve tumor
control (Fig. 8a, b), indicating that FasL-mediated apoptosis was
the dominant suppressive mechanism of PMN-MDSC in this
model system. Those results indicate that FasL neutralization can
improve the efﬁcacy of immunotherapy based on ACT.
To explore whether FasL neutralization can also increase the
efﬁcacy of immunotherapy based on immune checkpoint
inhibitors, we ﬁrst set up experiments in which we treated mice
bearing induced TiRP tumors with ACT combined with anti-
CTLA4 and anti-PD1 antibodies. The addition of immune
checkpoint inhibitors failed to improve tumor rejection, unless
it was combined with FasL neutralization and Ly6G-depletion
(Fig. 8c). This improved tumor control was, however, similar to
the one observed with ACT combined with Fas-Fc ± anti-Ly6G
(Fig. 8a, b). These results indicate that TiRP tumors display
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additional immunosuppressive mechanisms that make them
insensitive to immune checkpoint inhibitors. To further explore
potential synergy between immune checkpoint inhibitors and
FasL neutralization, we treated mice bearing transplanted
T429.11 tumors with anti-CTLA4 and anti-PD1. We observed
no tumor growth inhibition (Fig. 8d). However, when we
combined anti-CTLA4 and anti-PD1 with Fas-Fc we observed a
signiﬁcant tumor growth inhibition (P= 0.0004, two-way
ANOVA). When we also depleted PMN-MDSC in those mice
we observed no further increased tumor growth inhibition,
indicating that MDSC do not contribute other major immuno-
suppressive mechanisms in this setting. Although their recruit-
ment is lower than in induced TiRP tumors, MDSC are also
present in transplanted T429.11 tumors (Fig. 6a) and they express
high levels of FasL (FasL MFI was 2879 and 2758 for transplanted
and induced tumors, respectively, mean of 10 mice each).
Therefore, they seem to contribute to resistance to immune
checkpoint therapy, although it is possible that other FasL-
expressing cells also contribute. Altogether, these results indicate
that FasL neutralization has the potential to improve the efﬁcacy
of immunotherapy based not only on adoptive cell therapy but
also on immune checkpoint inhibitors.
A striking feature of this immunosuppressive mechanism is its
antigen-speciﬁc nature: only anti-tumor CD8+ T cells are affected
by apoptosis and disappear. This speciﬁcity likely results from the
fact that antigenic activation strongly increases Fas expression at
the surface of CD8+ T cells. This was conﬁrmed when we isolated
spleen cells from TiRP-tumor-bearing mice and incubated them
with L1210.P1A.B7-1 cells to activate P1A-speciﬁc T cells: after
48 h, we compared Fas expression on CD8+ T cells that were
P1A-speciﬁc or not (Supplementary Fig. 10a). Fas expression was
much higher on P1A-speciﬁc CD8+ T cells, which were the only
CD8+ T cells that were activated in these experimental conditions,
as indicated by CD69 expression. Moreover, when we incubated
these T cells with FasL, only P1A-speciﬁc CD8+ T cells underwent
apoptosis (Supplementary Fig. 10b). We also observed that IFNγ
further increased Fas expression on activated CD8+
T cells (Supplementary Fig. 4c). The latter ﬁnding likely
contributes to explain the reduced TIL apoptosis we observed
in mice treated with IFNγ-neutralizing antibodies (Fig. 4c). As
FasL is already expressed by MDSC before ACT, and therefore
probably does not depend on IFNγ produced by TIL, the pro-
apoptotic effect of IFNγ in this setting likely results from
increased expression, on activated T cells themselves, of both Fas
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and FasL, according to the well-described phenomenon of
activation-induced cell death (AICD), an immune checkpoint
process that prevents excessive T-cell activity by inducing Fas/
FasL-mediated suicide/fratricide killing of activated T cells28, 29.
AICD, however, is expected to occur in transplanted tumors, as
well as in induced tumors, and therefore cannot account for the
increased TIL apoptosis observed in induced tumors, which
rather appears to be triggered by FasL-expressing MDSC that are
enriched in these tumors.
Relevance to human tumors. To determine whether FASLG
expression was associated with disease progression in human
tumors, we used The Cancer Genome Atlas (TCGA) database to
compare the survival of patients bearing tumors expressing dif-
ferent levels of FasL. In most tumor types, high FASLG transcript
levels were associated with a relatively better survival than low
levels. This difference was statistically signiﬁcant in cutaneous
melanoma (P= 0.000014), head-and-neck squamous cell carci-
noma (P= 0.011) and breast carcinoma (P= 0.0078) (Fig. 9a–c).
In sharp contrast, high FASLG expression in renal cell carcinoma
(P= 0.04) and uveal melanoma (P= 0.000059) was associated
with signiﬁcantly worse prognosis (Fig. 9d, e). It is noteworthy
that these two tumor types are also those that diverge from most
other malignancies by their shorter survival associated with
higher TIL inﬁltration30–32. We therefore considered the possi-
bility that FASLG expression in human tumors was in fact
associated with T-cell inﬁltration. Consistently, expression of
FASLG in the main TCGA tumor types was strongly correlated
with the levels of T-cell-speciﬁc transcripts such as IFNG (shown
for melanoma in Fig. 9f), CD3E and CD8B (not shown). FASLG
transcript levels in tumors thus reﬂect TIL abundance and
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activity, in line with the selective expression of FasL in activated
T cells, and cannot be used as an independent prognostic factor.
Interestingly, a similar correlation with TIL inﬁltration was
observed for the transcript levels of IDO1 and PD-L1, two well-
known immune checkpoints that are induced by T-cell activation
and involved in adaptive tumoral resistance, as ascertained by the
clinical beneﬁt obtained with speciﬁc inhibitors12.
Discussion
Collectively, our results establish a dominant mechanism of
resistance to anti-tumor immunity in the TiRP model of
inﬂammatory melanoma, characterized by the induction of TIL
apoptosis through FasL expression by PMN-MDSC inﬁltrating
the tumor. Our results also illustrate, for the ﬁrst time, the
strikingly different behavior of autochthonous vs. isogenic
transplanted tumors, which are efﬁciently controlled by immu-
notherapy. The long-standing interaction between the host and
the autochthonous tumor growing progressively among normal
tissues results in a state of abnormal inﬂammation4, which allows
immunological tolerance of the tumor and is characterized by
enrichment in PMN-MDSC. Those cells express high amounts of
FasL, which then induces apoptosis of tumor-speciﬁc CD8+
T lymphocytes inﬁltrating the tumor and their progressive
depletion from the periphery. These results not only conﬁrm the
potential of targeting PMN-MDSC to reduce tumor-induced
immunosuppression, but also identify FasL as a promising target
whose neutralization could increase the clinical success of cancer
immunotherapy.
The role of FasL in mediating tumoral immune resistance has
been discussed for many years, following an initial report about
FasL expression by melanoma cells triggering TIL apoptosis33.
Several reports subsequently showed that enforced expression of
high-levels of FasL in tumor cells induced inﬂammation asso-
ciated with recruitment and activation of neutrophils resulting in
tumor rejection34, 35. These conﬂicting results initiated what was
called the Fas-counterattack controversy36. The issue was further
complicated by the poor speciﬁcity of the anti-FasL antibodies
available at the time, the relative role of membrane-bound vs.
soluble FasL, which does not trigger apoptosis, and the inter-
ference of FasL expression by other cells, including the T cells
themselves in the process of AICD36–38. Subsequent work partly
clariﬁed the controversy, by suggesting that the pro-inﬂammatory
role of FasL was dependent on high expression levels obtained by
enforced FasL expression, and showing that it was not observed
with tumors expressing FasL naturally, in which case FasL down-
regulation reduced tumorigenicity, in line with the immunosup-
pressive role of FasL39. Another key aspect is the type of cells
expressing FasL: contrary to the previous work discussed above,
in the TiRP model we did not so much observe FasL expression
on tumor cells but rather on PMN-MDSC.
Similarly, recent work highlighted the immunosuppressive role
of FasL expressed by endothelial cells in ovarian cancer40. In this
work, FasL-mediated apoptosis of anti-tumor T cells was shown
to prevent access of CD8+ T cells to tumor nests in ovarian
carcinoma40. This was linked to FasL expression by tumor
endothelia, inducing apoptosis of T cells reaching the tumor
vasculature, thereby preventing T-cell extravasation. Despite
similarity in the mode of T-cell execution, the mechanism of our
model is different, because TIL extravasation and inﬁltration is
not prevented, but TILs are induced to apoptosis by PMN-MDSC
within tumor nests. In practice, however, our observations concur
with those of Motz et al. in deﬁning FasL as a relevant drug target
whose neutralization could improve the efﬁcacy of cancer
immunotherapy. A recent study highlighted an additional beneﬁt
of neutralizing FasL in the context of ACT41. This study
compared the anti-tumor efﬁcacy of ACT making use of naive or
memory anti-tumor CD8+ T cells, or a mix of both. The latter
condition would mimic the clinical situation in cancer patients. It
is known that naive CD8+ T cells are more efﬁcient due to better
persistence after ACT. The authors showed that when naive
CD8+ T cells are mixed with memory CD8+ T cells and used for
ACT, they undergo a precocious differentiation that limits their
anti-tumor efﬁcacy. This precocious differentiation is driven by
memory CD8+ T cells through non-apoptotic Fas signaling: FasL
neutralization prevents this precocious differentiation of naive
CD8+ T cells and increases the efﬁcacy of ACT in this setting. We
only used naive CD8+ T cells and injected them after short-term
in vitro activation, so this effect does not explain the beneﬁcial
effect of FasL neutralization in our experimental setting. But it
provides an additional rationale for FasL neutralization in clinical
protocols of ACT, in which the autologous CD8+ T cells used are
usually a mix of naive and memory CD8+ T cells.
Although the dominant mechanism of T-cell cytotoxicity relies
on delivery of apoptosis-inducing granzymes into target cells42,
the FasL pathway also contributes, mostly to bystander cell kill-
ing. Such killing of stromal cells through FasL was found to be
required for complete tumor rejection in the context of ACT43.
However, the major role of the FasL pathway in the immune
system is to promote activation-induced cell death, which entails
fratricide and/or suicide death of T cells induced to express high
levels of Fas and FasL upon activation. This counter-regulatory
mechanism prevents excessive T-cell activity, and as such qua-
liﬁes as an immune checkpoint mechanism, whose inactivation
should beneﬁt cancer immunotherapy. This notion is supported
by the phenotype of gld and lpr mice, which are genetically
deﬁcient in FasL and Fas, respectively, and display autoimmune
phenotypes44–47.
In sum, the potential beneﬁts of FasL neutralization for cancer
immunotherapy, particularly in the context of adoptive cell
therapy, are fourfold: (i) preventing TIL apoptosis induced by
FasL-expressing PMN-MDSC, (ii) improving CD8+ T-cell inﬁl-
tration into the tumor by preventing apoptosis induced by
endothelial cells, (iii) improving T-cell persistence at the tumor
site by inhibiting the immune checkpoint relying on AICD, (iv)
improving T-cell persistence and activity by preventing pre-
cocious differentiation of naive T cells induced by co-injected
memory T cells. Strategies aimed at neutralizing FasL in combi-
nation with clinical approaches of cancer immunotherapy are
therefore warranted.
Methods
Mice. TiRP-10B;Ink4a/Arfﬂox/ﬂox mice2 contain an inducible transgene which is
controlled by the tyrosinase promoter and drives expression of H-Ras and of
Trap1a, which encodes a MAGE-type tumor antigen. They were backcrossed to a
B10.D2 background (TiRP mice) and bred to homozygosity (TiRP-10B+/+;Ink4a/
Arfﬂox/ﬂox). B10.D2;Ink4a/Arfﬂox/ﬂox (TiRP-10B−/−) mice were used as controls and
as recipients for tumor transplantation experiments. TCRP1A mice heterozygous
for the H-2Ld/P1A35-43-speciﬁc TCR transgene10 were kept on the B10.D2;Rag1−/−
background. For all the in vivo treatments, mice were randomly divided into
groups. Investigators were blinded to the group allocation during the animal
experiments. Age-matched littermate mice of both sexes between 5 and 7 weeks of
age were used for all in vivo experiments. All mice used in this study were pro-
duced under SPF conditions at the animal facility of the Ludwig Institute for
Cancer Research. All the rules concerning animal welfare have been respected
according to the 2010/63/EU Directive. All procedures were performed with the
approval of the local Animal Ethical Committee, with reference 2015/UCL/MD/15.
Tumor induction with 4OH-Tamoxifen. A fresh solution of 4OH-Tamoxifen was
prepared by dissolving 4OH-Tamoxifen (Sigma Aldrich and Imaginechem) in
100% ethanol and mineral oil (ratio 1:9) followed by 30-min sonication, and
injected twice s.c (4 mg/200 µl) in the neck area of anesthetized TiRP mice two
weeks apart. The therapeutic experiments were performed exclusively with mice
bearing unpigmented Amela tumors. Unless mentioned otherwise, mice with
pigmented tumors (Mela) were excluded due to different tumor growth kinetics4.
Tumor volume (in mm3) was calculated by the following formula: volume=length/
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2×width2. For occasional mice that developed more than one tumors we only
considered the tumor that appeared ﬁrst.
Cell lines. T429.11, T429.6 and T429.18 clones were derived from an induced
Amela TiRP tumor referred to as T4294. They were cloned from the T429 induced
melanoma primary tumor line. The expression of the transgene2 was evaluated in
all three T429 clones and T-cell recognition was tested for each of them in vitro
using TCRP1A CD8+ T cells. P511 is an azaguanine-resistant variant of P81548, 49.
P1204 is a P815AB-negative variant carrying a deletion of gene Trap1a48, 49. L1210.
P1A.B7-1 cells were obtained by transfection of L1210.P1A cells with the murine
B7-1 cDNA cloned into plasmid pEFBOS50. All cells were maintained at 37 °C with
8% CO2. Unless otherwise speciﬁed, all culture media are IMDM (GIBCO) con-
taining 10% fetal bovine serum supplemented with L-arginine (0.55 mM, Merck),
L-asparagine (0.24 mM, Merck), glutamine (1.5 mM, Merck), beta-
mercaptoethanol (50 µM, Sigma), 50 Uml−1 penicillin and 50 mgml−1 strepto-
mycin (Life Technologies) (complete medium). Cell lines were tested for myco-
plasma contamination.
Adoptive transfer of TCRP1A CD8+ T cells. P1A-speciﬁc CD8+ T cells were
isolated from spleens and lymph nodes of TCRP1A mice using anti-CD8α
MicroBeads (Miltenyi Biotec), and stimulated in vitro by co-culture for 4 days with
irradiated (10,000 rads) L1210.P1A.B7-1 cells51 (105 of each cell type per well in
48-well plates) in IMDM complete medium. After puriﬁcation on a Ficoll gradient
on day 4, 107 living TCRP1A CD8+ T cells were injected i.v. in 200 µl PBS.
Vaccine and antibodies treatment. TiRP mice were immunized against P1A-
tumor antigen by a heterologous prime-boost regimen consisting of a ﬁrst injection
of an Adeno.Ii.P1At (108 PFU/mouse/100 µl) followed, 15 days later, by SFV.P1A
(107 IU/mouse/100 µl)6. Both viruses were given intradermally. Anti-PD1 (BioX-
cell, clone RMP1-14, Rat IgG2a, 200 µg/mouse i.p.) and anti-CTLA4 (BioXcell,
clone 9H10, Syrian Hamster IgG2, 40 µg/mouse i.p.) treatment were started at the
time of tumor appearance every 3 days for a total of 4 injections. Control mice
received isotype controls (for CTLA4: BioXcell, Polyclonal Syrian Hamster IgG; for
PD-1, BioXcell, Rat IgG2a, clone 2A3).
For the control immunization against P91A (Fig. 1c), mice received 4
intramuscular injections every two weeks of P91A peptide (50 µg) in PBS, mixed
v/v with AS15 adjuvant52 kindly provided by GlaxoSmithKline, Belgium. For
in vivo neutralization of IFNγ, mice received 0.5 mg anti-mouse IFNγ (BioXcell,
clone XMG1.2,) 1 day before ACT.
For the intra-tumoral depletion of Ly6Gh MDSC, presented in Fig. 7f, mice
received 200 µg/mouse of antibody to Ly6G (BioXcell, clone 1A8, Rat IgG2a) or
isotype control (BioXcell, Rat IgG2a, clone 2A3) every 3 days starting 4 days before
ACT.
For the in vivo antibody treatment combined with adoptive cell transfer
(Fig. 8a–c), anti-Ly6G (200 µg/mouse except the ﬁrst injection which was
400 µg/mouse, twice a week), and Fas-Fc (150 µg/mouse, two injections per week)
treatment started when the tumor size reached 500 mm3. The anti-CTLA4
(100 µg/mouse) and anti-PD1 antibodies (200 µg/mouse) were injected 4 times at a
3 days interval i.p. 1 day after the anti-Ly6G and Fc-Fas injection. The
corresponding isotype controls were injected accordingly. Mice received 107
activated TCRP1A CD8+ T cells (ACT) 3 days after Fas-Fc and anti-Ly6G
injection. Tumor size was monitored every 2 days.
For the in vivo antibody treatments (Fig. 8d), anti-Ly6G (BioXcell, clone 1A8,
Rat IgG2a, 200 µg/mouse except the ﬁrst injection which was 400 µg/mouse, twice a
week), and Fas-Fc (150 µg/mouse, two injections per week) treatment started when
the tumor size reached 50–150 mm3. The anti-CTLA4 (BioXcell, clone 9H10, 100
µg/mouse) and anti-PD1 antibodies (BioXcell, clone RMP1-14, 200 µg/mouse)
were injected 4 times at 3-day intervals i.p. starting 1 day after the anti-Ly6G and
Fas-Fc injections. The corresponding isotype controls were injected accordingly.
Tumor size was monitored every 2 or 3 days.
Flow cytometry. H-2Ld/P1A and P91A tetramers (1 µM) were produced in our
Institute53. Antibodies used were: CD8α-PerCP (clone 53–6.7, Biolegend, 1 µg/mL);
CD69-APC (clone H1.2F3, Biolegend, 1 µg/mL); CD3ε-FITC (clone 17A2, Biole-
gend, 1 µg/mL); CD45-FITC, CD45-Alexa700 (clone 30-F11, Biolegend, 1 µg/mL);
Gr-1-APC, Gr-1-Bv421 (clone RB6-8C5, Biolegend, 1 µg/mL); Ly6C-PerCP (clone
HK1.4, Biolegend, 1 µg/mL); Ly6G-PE, Ly6G-Bv510 (clone 1A8, Biolegend,
1 µg/mL); CD11b-BV421 (clone M1/70, Biolegend, 1 µg/mL); CD178 (FasL) (clone
Kay-10, Biolegend, 2 µg/mL); CD31-PE/Cy7 (clone 390, Biolegend, 1 µg/mL);
CD95-PE/Cy7 (Fas) (clone Jo2, Becton Dickinson, 1 µg/mL) and corresponding
isotype controls. Viability dye eﬂuor780 (eBiosciences, 1:500) was used. Annexin
V-BV421 or Annexin V-APC (Biolegend, 1:50) was used to monitor apoptosis.
P1A antibody (clone P1A102B3, 1 µg/mL) was produced by immunizing P1A-KO
mice54 with a P1A peptide (CEEMGNPDGFSP) coupled to ovalbumin. Hybrido-
mas were sub-cloned and further screened for production of anti-P1A antibodies.
Clone P1A102B3 was selected and conﬁrmed to produce an IgG1 recognizing P1A
speciﬁcally and applicable for western blot, IHC, Flow cytometry and ELISA.
Quantitative RT-PCR. Total RNA isolated from tumor tissues were tested by qRT-
PCR using the following primers: Trap1a (P1A): forward: 5ʹ-AGC-TGA-GGA-
AAT-GGG-TGC-TG-3ʹ (exon 1), reverse: 5ʹ-CAG-CAT-TTT-CAC-ACC-TAC-
ACT-CCA-3ʹ (exon 2), probe: 5ʹ-FAM-CCA-TCA-TTT-AAG-GAA-GAA-TGA-
AGT-GAA-GTG-TAG-GAT-GA-TAMRA-3ʹ (exon 2). Ifng: forward: 5ʹ-TCA-
AGT-GGC-ATA-GAT-GTG-GAA-GAA-3ʹ, reverse: 5ʹ-TGG-CTC-TGC-AGG-
ATT-TTC-ATG-3ʹ, probe: 5ʹ-FAM-TCA-CCA-TCC-TTT-TGC-CAG-TTC-CTC-
CAG-TAMRA-3ʹ. Samples were assayed in triplicates and expression levels were
normalized to β-actin, which was tested with the following primers: forward actin:
5ʹ-CTC-TGG-CTC-CTA-GCA-CCA-TGA-AG-3ʹ, reverse actin: 5ʹ-GCT-GGA-
AGG-TGG-ACA-GTG-AG-3ʹ, probe actin: 5ʹ-FAM-ATC-GGT-GGC-TCC-ATC-
CTG-GC-TAMRA-3ʹ. Faslg was ampliﬁed using ROX SYBR MasterMix blue dTTP
using the following primers: forward: 5ʹ-TGA-ATT-ACC-CAT-GTC-CCC-AG-3ʹ,
reverse: 5ʹ-AAA-CTG-ACC-CTG-GAG-CC-3ʹ (Fig. 4d). In Fig. 4e, Faslg was
ampliﬁed using other primers and probe (Integrated DNA technologies, Mm.
PT.58.28447971). Gapdh (Mm.PT.39a.1) Il6 (Mm.PT.58.10005), Csf1 (Mm.
PT.58.11661276), Csf2 (Mm.PT.58.9186111), Csf3 (Mm.PT.58.7976206.gs), Cxcl1
(Mm.PT.58.42076891), Cxcl12 (Mm.PT.58.12038563), Ccl2 (Mm.PT.58.42151692),
Tgfb1 (Mm.PT.58.11254750), Ccl7 (Mm.PT.58.17719534), Cxcl5 (Mm.
PT.58.29518961.g) primer and probe were purchased from Integrated DNA
technologies.
Fas silencing in TCRP1A CD8+ T cells. Silencing of Fas in activated TCRP1A
CD8+ T cells was achieved by using Accell siRNA (1 µM) (Dharmacon), with
sequence 5ʹ(P)-GUGCAAGUGCAAACCAGAC(dTdT)-3ʹ. After 1 day of activa-
tion, TCRP1A CD8+ T cells were incubated with 1 µM Accell control or Fas siRNA
in IMDM complete medium without serum for 24 h, then the medium was
replaced with IMDM complete medium with serum. The silencing procedure was
repeated on day 3. On day 4, 107 TCRP1A CD8+ T cells were adoptively trans-
ferred into mice bearing induced tumors. Silencing efﬁciency was monitored by
Western blot using anti-Fas antibody (Santa Cruz, FL- 335, 1:1000). Blots were
stripped and reprobed with a rabbit anti-mouse monoclonal antibody to GAPDH
(Cell Signaling, 14C10, 1:5000).
Production of soluble Fas-Fc. Recombinant soluble dimers of the murine Fas
death receptor extracellular domain (ECD) were produced in Drosophila S2 cells
(Invitrogen). The sequence coding for the ECD of murine Fas was fused in frame to
the sequence coding for the murine FcIgG2A portion to allow dimerization of the
fusion protein. A sequence coding for a derivative of the human IL-9 signal peptide
was added at the 5ʹ end of the fusion gene to allow secretion of the recombinant
protein. The recombinant gene was cloned into a derivative of the expression
vector pRMHA3, which contains a neomycin-resistance gene and a copper indu-
cible promotor from the Drosophila melanogaster metallothionein gene. Droso-
phila S2 cells were transfected and stable transfectants selected using 1.5 mg/ml of
G418 antibiotic (Roche). Production of the recombinant protein was induced in the
cultured cells by the addition of 0.5 mM CuSO4. The protein was puriﬁed from the
cell culture supernatant by afﬁnity chromatography on a protein A sepharose
column (GE Healthcare).
In vivo apoptosis staining. Four days after ACT, tumor-bearing mice received an
i.v. injection of NIR-FLIVO™ 690 Control (8.5 µg/mouse) or NIR-FLIVO™ 690
(NIR-FLIVO™-DyLight® 690-VAD-FMK in vivo Apoptosis Tracer, Immu-
noChemistry Technologies, 8.5 µg/mouse) 4 h before killing. TCRP1A CD8+ T cells
were then identiﬁed using H-2Ld-P1A tetramers and anti-CD8α antibody and
analyzed for FLIVO staining by FACS.
ELISA. IFNγ secretion was evaluated by ELISA (Biolegend) in the supernatant of
tumor homogenates after 24 h of culture in IMDM medium.
T-cell apoptosis in organotypic tumor slices in vitro. Fresh tumor tissue slices of
250–300 μm thickness were prepared using the microtome (LEICA, Vibratome
VT1200), and cultured on organotypic inserts for 24 h (Millipore) in 4 ml IMDM
complete medium. One million TCRP1A CD8+ T cells pre-labeled with CMAC
(CellTracker Blue CMAC Dye) were added for 24 h. After washing and OCT
embedding, cryosections (7 μm) of these organotypic tumor tissues were stained for
apoptosis using FLICA pan-caspase reagent (ImmunoChemistry Technologies,
1:150) and scanned with MIRAX digital microscope. Quantiﬁcation was performed
using Biopix software.
MDSC puriﬁcation. After mechanical and enzymatic dissociation of induced TiRP
tumors, MDSC were enriched by centrifugation on Ficoll-Paque Plus (GE
Healthcare). Ly6Gh cells were further puriﬁed by magnetic sorting (Miltenyi) and
conﬁrmed as PMN-MDSC by FACS analysis (Gr-1h, CD11b+, Ly6Clo and Ly6Gh).
Tumor transplantation with MDSC isolated from induced tumors. Single cell
suspensions were prepared from induced Amela TiRP tumors and from T429.11
transplanted tumors using gentleMACS™ Dissociator. MDSCs were puriﬁed from
the induced TiRP tumor suspension (as described above) and mixed with the
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transplanted tumor suspension (MDSC/T429.11 ratio: 1/4). The T429.11 tumor
cell suspensions mixed or not with isolated MDSC were injected intradermally into
naive B10.D2;Ink4a/Arfﬂox/ﬂox mice, on the left and right ﬂank respectively. When
the tumor volume of the left ﬂank reached around 500 mm3, the mice received
adoptive cell transfer of TCRP1A speciﬁc CD8+ T cells. The tumor size was
measured every 4 days from the day of the adoptive cell transfer (n = 8 mice).
MDSC-mediated T-cell suppression assay. TCRP1A T CD8+ T cells activated
in vitro for 4 days with irradiated L1210.P1A.B7-1 cells were puriﬁed, washed,
counted and 100 µl of 2 × 105 cells viable cells were seeded in a 96-well plate in
IMDM complete medium. Ly6G+ MDSC from induced tumors were isolated and
puriﬁed as above. TCRP1A CD8+ T cells were co-cultured with Ly6G+ MDSCs at
the indicated ratios for 3 days at 37 °C. TCRP1A T cells were then puriﬁed using
anti-CD8 microbeads. Their proliferation was assessed in an 18-hour 3H-
Thymidine incorporation assay. TCRP1A CD8+ T cells co-cultured with Ly6G
+-MDSC for 3 days as above and puriﬁed using anti-CD8 microbeads were tested
for cytolytic activity in a standard 4 h-chromium release assay, using P511 cells as
P1A+ target cells and P1A− cells P1204 as cold target competitors.
Statistics. Statistical analyses were performed using Prism 6 (GraphPad Software).
Comparison between two groups was performed using the unpaired Student t-test,
while two-way analysis of variance (ANOVA) was used to compare the effects of
different treatments on tumor growth. P values< 0.05 were considered signiﬁcant
(P-value < 0.05 was annotated *;< 0.01 **; < 0.001 ***;< 0.0001 ****).
The tumoral gene expression values and patient survival data from The Cancer
Genome Atlas (TCGA) database were retrieved from the cBioPortal’s Cancer
Genomic Data Server using the CGDS-R package (http://www.cbioportal.org/
cgds_r.jsp) and analyzed with the R software using the “survival” package. The
patients were divided in two groups according to high and low FASLG expression
level, separated by the median value. Their survival curves were compared using
Cox proportional hazard regression model. A P-value below 0.05 was considered
signiﬁcant.
Data availability. The TCGA data referenced during the study are available in a
public repository from the TCGA website (https://cancergenome.nih.gov). The
authors declare that all other data supporting the ﬁndings of this study are available
within the article and its supplementary information ﬁles and from the corre-
sponding author upon reasonable request.
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